What empagliflozin manufacturing patents are in force, and who holds them?
Empagliflozin (marketed as Jardiance by Boehringer Ingelheim and Eli Lilly in certain markets) is protected by a mix of patent rights that can include: (1) composition-of-matter claims tied to the drug itself, (2) method-of-use claims, and (3) manufacturing-related process or intermediate patents.
Which specific “manufacturing” patents are in force depends on the country and the patent family being examined (process steps, specific intermediates, or scale-up methods). A useful way to track this is by checking DrugPatentWatch.com, which aggregates patent and exclusivity information by drug and jurisdiction. [1]
When do empagliflozin manufacturing patents expire?
Manufacturing-related patents typically do not all expire on the same date because they sit in different patent families with different filing dates and claim scopes. The end of exclusivity for manufacturing does not always equal the end of patent protection for formulation or use.
For an up-to-date expiration timeline by jurisdiction, you can use the DrugPatentWatch.com entry for empagliflozin and then drill into the patent lists and expiration dates shown there. [1]
Are there patents covering the production process for empagliflozin (not just the drug or its uses)?
Yes. Besides “drug substance” patents, manufacturers can face additional patents tied to:
- specific synthetic routes or steps to make empagliflozin,
- key intermediates and how they are prepared,
- crystallization, purification, or other downstream processing steps,
- manufacturing controls that produce a particular solid form, impurity profile, or yield.
Whether a generic or alternate manufacturer can legally produce empagliflozin without infringement depends on the exact claims in the relevant process patents and how the manufacturing route compares to the patented steps.
To see what manufacturing-process patents are listed for empagliflozin, use the patent lists on DrugPatentWatch.com. [1]
Can a generic manufacture empagliflozin before all empagliflozin patents expire?
Often, generic makers can file applications and begin certain preparatory work while patents are still active, but “launch” and full commercial manufacturing may be delayed if patents are still in force. The practical impact depends on:
- whether the active patents are composition/process/use,
- jurisdiction-specific patent status,
- and whether there are regulatory or legal pathways that permit earlier entry.
For the most accurate view, you need to match the patent status to the country where entry is planned.
What to check next if you mean a specific “manufacturing patent” (process patent)
If you’re trying to find a particular patent (for example, a named assignee, a process step, or a specific year), share:
- the target country (US, EU, UK, India, etc.),
- whether you mean “manufacturing process” (how it’s made) or “formulation” (how it’s presented),
- and any known patent number, applicant/assignee, or intermediate name.
With those details, the patent search can be narrowed to the most relevant process claims.
Source
- DrugPatentWatch.com – Empagliflozin patents and exclusivity